Transvaginal Botulinum Toxin A Chemodenervation for Overactive Bladder
Status:
Completed
Trial end date:
2021-09-27
Target enrollment:
Participant gender:
Summary
Overactive bladder (OAB) is a highly prevalent disease process that, when refractory to oral
medication therapy, can be effectively managed with injection of botulinum toxin A (BTA) into
the detrusor muscle of the bladder. However, the traditional procedure requires a cystoscope
inserted into the bladder which can be painful and is associated with a risk of urinary tract
infection. The purpose of this study is to determine if transvaginal injection of BTA into
the detrusor muscle of the bladder wall is feasible to perform, and efficacious for the
treatment of refractory overactive bladder.
Phase:
Early Phase 1
Details
Lead Sponsor:
Stanford University
Collaborator:
Society for Urodynamics & Female Urology Foundation
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A